A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

What Was Tested

In this phase 3 trial, researchers set out to test Eloralintide.

Participation in the study will last about 75 weeks.

It had five arms (groups): one (experimental), one (experimental), one (experimental), one (experimental) and Placebo (placebo comparator).

Participants will receive eloralintide subcutaneously (SC).

Participants will receive eloralintide SC.

Participants will receive eloralintide SC.

The registry classes the interventions as drug.

Who Took Part

1035 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have type 2 diabetes. Are on stable treatment for type 2 diabetes for at least 90 days prior to screening. Have a BMI ≥ 27 kg/m2.

The full record lists 4 inclusion and 16 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening); have type 1 diabetes; have taken any of the following antihyperglycemic medications within 90 days before screening:.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

The participants were allocated by chance, so the Eloralintide group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Eloralintide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2025-12-15 with completion listed for 2028-01.

It ran at 143 sites in United States (60), China (16), Japan (15), Spain (9), Poland (8) and Germany (7).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percent Change from Baseline in Body Weight (time frame: Baseline, Week 64).

It also tracked 16 secondary outcomes, for example Percent Change from Baseline in Total Body Fat Mass, Change from Baseline in Waist Circumference, Change from Baseline in Hemoglobin A1c (HbA1c), Percent Change in Baseline in Triglycerides, Change from Baseline in Systolic Blood Pressure and Change from Baseline in Body Mass Index (BMI).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Eloralintide in 1035 people.

With 1035 participants it is a large trial for this field.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Eloralintide compound page, all human trials.